HENGRUI PHARMA rose 11.49% in regular trading, with shares at HK$49.86. The key catalyst was the company’s latest quarterly results released on October 27, which showed a sharp acceleration in third-quarter profit alongside solid revenue growth.

For the third quarter, revenue was RMB8.953 billion, up 20.55% year over year, while net profit reached RMB2.458 billion, up 88.92%, and non-recurring adjusted net profit rose 90.93% to RMB2.514 billion. For the first nine months, revenue increased 5.26% to RMB24.409 billion and net profit rose 20.38% to RMB6.923 billion. The company also said rising out-licensing income contributed to the earnings improvement, while innovation drug sales for the first nine months reached RMB13.871 billion, up 17.05%.